Home Cart Sign in  
Chemical Structure| 957217-65-1 Chemical Structure| 957217-65-1

Structure of BTZ043 Racemate
CAS No.: 957217-65-1

Chemical Structure| 957217-65-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BTZ043 racemate is a decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) inhibitor acting as an antimycobacterial agent that kill Mycobacterium tuberculosis.

Synonyms: BTZ10526038; Benzothiazinone 10526038

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BTZ043 Racemate

CAS No. :957217-65-1
Formula : C17H16F3N3O5S
M.W : 431.39
SMILES Code : O=C1N=C(N(CC2)CCC32OCC(C)O3)SC4=C([N+]([O-])=O)C=C(C(F)(F)F)C=C14
Synonyms :
BTZ10526038; Benzothiazinone 10526038
MDL No. :MFCD22420808

Safety of BTZ043 Racemate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
THP-1 46 μg/ml (TD50) 3 days Evaluate cytotoxicity, showing low cytotoxicity PMC4505264
A549 51 μg/ml (TD50) 3 days Evaluate cytotoxicity, showing low cytotoxicity PMC4505264
Huh7 50 μg/ml (TD50) 3 days CD13 promotes HCC cell proliferation, invasion, and sorafenib resistance PMC4505264
HepG2 47 μg/ml (TD50) 3 days CD13 promotes HCC cell proliferation, invasion, and sorafenib resistance PMC4505264
Mycobacterium smegmatis 4 ng/ml (9.2 nM) Observe the growth inhibition and cell lysis effect of BTZ043 on M. smegmatis PMC3128490
Mycobacterium tuberculosis H37Rv 1 ng/ml (2.3 nM) 72 hours Evaluate the bactericidal effect of BTZ043 on M. tuberculosis H37Rv, showing significant killing effect within 72 hours PMC3128490
Mycobacterium smegmatis 0.0007 ng/ml Observe the growth inhibition and cell lysis effect of BTZ043 on M. smegmatis PMC3958311
Mycobacterium tuberculosis H37Rv 0.0003 ng/ml 7 days Evaluate the bactericidal effect of BTZ043 on M. tuberculosis H37Rv, showing significant killing effect within 72 hours PMC3958311
Non-replicating Mtb in caseum 512 µM 7 days To evaluate the activity of BTZ-043 against non-replicating Mtb, results showed limited activity in caseum. PMC10648937
Mycobacterium tuberculosis Erdman 0.008 µg/mL 10 days To evaluate the antimicrobial activity of BTZ-043 against actively replicating Mtb, results showed BTZ-043 has bactericidal activity. PMC10648937
Mycobacterium tuberculosis H37Rv 0.16 μg/ml 1 week Evaluate the bactericidal effect of BTZ043 on M. tuberculosis H37Rv, showing significant killing effect within 72 hours PMC4505264

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice (BALB/c and IL-13 transgenic mice) Tuberculosis model (BALB/c mice and IL-13 transgenic mice) Oral gavage 50, 100, 250, 500, 1000 mg/kg/day (BALB/c mice); 250 mg/kg/day (IL-13 transgenic mice) 5 days per week for 4, 6, or 8 weeks (BALB/c mice); 10 consecutive days (IL-13 transgenic mice) To evaluate the antituberculosis activity of BTZ-043 in standard and advanced mouse models. Results showed that BTZ-043 exhibited dose- and time-dependent bactericidal activity in BALB/c mice and effectively reduced bacterial burden in both pulmonary and necrotic granulomas in IL-13 transgenic mice. PMC11742723
Mice Chronic tuberculosis model Oral 25 mg/kg 5 days per week for 4 weeks Evaluate the in vivo efficacy of PBTZ169 in the murine model of chronic TB, showing that PBTZ169 has significantly greater bactericidal activity than BTZ043 at the same dose. PMC3958311
C3HeB/FeJ mice Tuberculosis infection model Oral 50, 100, 200 mg/kg 5 days per week for 8 weeks To evaluate the efficacy of BTZ-043 in a tuberculosis infection model, results showed significant reductions in lung and spleen bacterial burdens. PMC10648937
BALB/c mice Acute tuberculosis model Oral 50 mg/kg 5 days/week for 4 weeks Evaluate in vivo efficacy, did not show antituberculosis activity PMC4505264
Mice Tuberculosis model Oral or intravenous injection 5 mg/kg or 50 mg/kg Single dose To study the metabolic pathways and pharmacokinetic properties of SKLB-TB1001 in vivo, the results showed that SKLB-TB1001 was rapidly transformed into inactive metabolites in vivo, leading to a reduction in its potency in vivo. PMC6021648

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.32mL

0.46mL

0.23mL

11.59mL

2.32mL

1.16mL

23.18mL

4.64mL

2.32mL

References

 

Historical Records

Categories